Quick Answer
Theravance Biopharma, Inc. reported Net Income of $105.89 million for fiscal year 2025.
Theravance Biopharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $105.89M | +287.7% |
| 2024 | -$56.42M | -2.2% |
| 2023 | -$55.19M | -106.3% |
| 2022 | $872.13M | +537.3% |
| 2021 | -$199.43M | +28.3% |
| 2020 | -$278.02M | -17.6% |
| 2019 | -$236.46M | -9.7% |
| 2018 | -$215.52M | +24.5% |
| 2017 | -$285.40M | -49.7% |
| 2016 | -$190.67M | -4.6% |
| 2015 | -$182.22M | +23.1% |
| 2014 | -$237.04M | -51.7% |
| 2013 | -$156.28M | -1532.2% |
| 2012 | -$9.57M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.62M | +128.5% | -93.4% |
| June 30, 2025 | $54.84M | +431.8% | +503.8% |
| March 31, 2025 | -$13.58M | -16.4% | -6.9% |
| September 30, 2024 | -$12.70M | -41.9% | +23.2% |
| June 30, 2024 | -$16.53M | -5.7% | -41.7% |
| March 31, 2024 | -$11.66M | +47.2% | -30.3% |
| September 30, 2023 | -$8.95M | -101.0% | +42.8% |
| June 30, 2023 | -$15.64M | -91.0% | +29.2% |
- Theravance Biopharma, Inc. showed an increase of +287.7% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Theravance Biopharma, Inc.’s net income has grown by 1206.0% (from -$9.57 million to $105.89 million).
- The most recent figure is from Theravance Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: